MESO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mesoblast Ltd (MESO) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company has shown impressive revenue growth and financial flexibility, the missed earnings expectations, lack of significant trading trends, and neutral technical indicators suggest that it is better to wait for clearer signals or more favorable conditions before investing.
The MACD is slightly positive at 0.012, indicating mild bullish momentum, but the RSI at 49.836 is neutral, showing no clear trend. The moving averages are converging, and the stock is trading near its pivot level of 16.909, suggesting indecision in the market.
Revenue increased by 1503.1% to $51.3 million in 1H FY2026, driven by the successful launch of Ryoncil®.
Gross profit of $44.2 million and a strong cash balance of $130 million with an additional $125 million credit line enhance financial flexibility.
Increased R&D investment for expanding Ryoncil®'s indications shows a focus on long-term growth.
Missed GAAP EPS expectations with a significant loss of -$3.
No significant hedge fund or insider trading trends, indicating a lack of strong institutional or insider confidence.
Neutral technical indicators and lack of clear price momentum.
Mesoblast reported a 1H FY2026 revenue of $51.3 million, a 1503.1% increase, but missed EPS expectations with a loss of -$3.11. The company has a strong cash position of $130 million and secured a $125 million credit line, indicating solid financial flexibility. Increased R&D investment highlights a focus on future growth.
No recent analyst rating or price target changes are available for Mesoblast Ltd (MESO).
